To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00170924|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : November 8, 2011
Patients who have had high blood pressure for a long time may have diastolic dysfunction. Diastolic Dysfunction is when your heart has difficulty filling and emptying, and relaxing adequately.
This study is to find out if Valsartan) will improve the ability of the heart to fill, empty, and relax appropriately when given alone or with other medicines to treat high blood pressure.
|Condition or disease||Intervention/treatment||Phase|
|Diastolic Dysfunction Hypertension||Drug: Valsartan||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||317 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Multi-center, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effect of the Angiotensin II Antagonist Valsartan on Diastolic Function in Patients With Hypertension and Diastolic Dysfunction|
|Study Start Date :||August 2004|
|Actual Primary Completion Date :||June 2006|
|Actual Study Completion Date :||June 2006|
- Change from baseline in diastolic heart function at 38 weeks, measured by echocardiogram
- Change from baseline in the wall thickness of left heart ventricle after 38 weeks
- Change from baseline in the size (mass) left heart ventricle after 38 weeks
- Change from baseline in heart function after 38 weeks
- Change from baseline in circulating marker of ventricular function after 38 weeks
- Change from baseline in circulating marker of inflammation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00170924
|United States, New Jersey|
|East Hanover, New Jersey, United States, 07936|
|Study Director:||Novartis Pharmaceuticals||Novartis Pharmaceuticals|